Markets
markets
Luke Kawa

Whirlpool thinks you’ll buy more appliances after the election

Whirlpool Corp.’s earnings may be down significantly year on year, but still cleared the low bar that Wall Street set for the company. Shares of the seller of washing machines and other large appliances rose as much as 9% in early trading after reporting earnings per share of $3.43, well ahead of the $3.19 estimate (but below $5.45 for the same quarter in 2023).

One thing became clear during the conference call that followed this release: executives really think the looming election has been a clear negative for their business.

“Consumer confidence remains low and is impacted by the uncertainty ahead of the upcoming elections,” CEO Marc Bitzer said.

“Here in the US, with the election cycle going on, we do just expect an unusual pattern that will be a little slower and then should pick up significantly like we’ve seen historically,” James Peters, chief financial and administrative officer, said.

There were 10 references to the election on the call and 7 mentions of (poor) consumer sentiment. That compares to zero mentions of either during the Q3 2020 call (granted, we all may have had bigger things on our mind). But it’s also much more than 2016, when there were just three references to the election and consumer sentiment.

Who knows if a preelection malaise is more of an economic drag compared to prior cycles. But management teams are certainly talking about it more

It’s somewhat curious that Whirlpool’s C-suite is more focused on just getting the election over with, rather than expressing at least some concern about the outcome. The company was among those more whipsawed by shifts in trade policy during the Trump administration.

After Trump announced tariffs on imported washing machines in January 2018, Bitzer hailed this as “without any doubt, a positive catalyst for Whirlpool.” Then he watched as a separate set of tariffs raised the company’s expenses and contributed to a 36% decline in the share price that year. 

Combining its focus on the need for the US housing market to reboot and its sensitivity to changes in trade policy, Whirlpool may be one of the companies for which decisions made in DC — whether at the White House or the Eccles Building — matter the most.

More Markets

See all Markets
markets

Trump administration says tariffs on Chinese semiconductor imports are coming... in 2027

After a year-long investigation into China’s tactics to bolster its domestic semiconductor industry, the US has determined that its practices are “unreasonable” and is going to do something about that in 18 months.

The Trump administration’s office of the US trade representative said today that it plans to impose tariffs on imports of Chinese semiconductors at a rate higher than 0% to be decided at least 30 days before June 23, 2027.

“China’s pursuit of its dominance goals has severely disadvantaged US companies, workers, and the U.S. economy generally through lessened competition and commercial opportunities and through the creation of economic security risks from dependencies and vulnerabilities,” per the USTR’s notice of action.

These levies, should they come to pass, would apply to silicon, diodes, transistors, and more.

US markets were completely unbothered by this revelation, likely because there is no immediate action against Chinese semi companies and therefore no disruption to business-as-usual. This represents a punting of a contentious matter, similar to how China delayed restrictions on rare earth shipments as part of a deal between Presidents Trump and Xi following their October meeting.

It’s another sign of a thaw in the US-China relations over the hot-button issue of semiconductors after President Trump gave Nvidia the go-ahead to sell its H200 chips to buyers in the world’s second-largest economy.

markets

ServiceNow strikes deal to buy cybersecurity firm Armis for $7.75 billion in cash

ServiceNow has agreed to acquire cybersecurity startup Armis for $7.75 billion in an all-cash deal, the largest purchase in the company's history.

That price tag is $750 million above what Bloomberg suggested was the top end of what Armis would cost just last week, and about $1.65 billion above what the company had been valued at in a November funding round.

Armis had been readying itself for an IPO, with many major investors looking to take a stake in the firm.

Instead, it’s now a key cog in the software platform company’s bid to lean on cybersecurity features to bolster its appeal to customers in a world in which the rise of AI adds to the potential threats of business disruptions and data breaches.

Per the press release:

As rapid AI adoption expands the attack surface for organizations, real-time visibility into vulnerabilities and actionable insights for what to fix first are critical to minimize risk and strengthen security posture. The acquisition of Armis will extend and enhance ServiceNow’s Security, Risk, and OT portfolios in critical and fast-growing areas of cybersecurity and drive increased AI adoption by strengthening trust across businesses’ connected environments.

markets

Novo Nordisk rallies after FDA weight loss pill approval

Novo Nordisk’s US-listed shares are up 7% in pre-market trading on Tuesday after the US Food and Drug Administration approved its Wegovy weight loss pill on Monday evening.

Now the first pill of its kind to receive approval from the regulator, Novo’s Wegovy pill is expected to launch in the US in early January 2026, and awaits the European Medicines Agency and other regulatory authorities’ approval after submitting for review in the second half of 2025, per the company’s press release. The 1.5 milligram starting dose of the pill will be sold at an introductory price of $149 a month.

“The pill is here. With today's approval of the Wegovy® pill, patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy® injection,” said Mike Doustdar, president and CEO of Novo Nordisk.

The approval was based on Novo’s Oasis 4 trial, which found participants who took 25 milligram doses of Wegovy pills daily lost 16.6% of their body weight over a 64 week period.

The approval will give Novo — which lost more than 50% of its market cap this year after Eli Lilly took the crown in weekly US prescriptions for injectable weight-loss drugs with its product Zepbound — a first-mover advantage in the expanding market. Lilly, which is down some 1% in pre-market trading today, has said its own oral drug orforglipron could be approved by March 2026.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.